Sensyne Health, a British clinical AI technology company, has announced it has signed a £470,000 agreement with the Department of Health & Social Care to conduct the second stage of a pilot study of its MagnifEye technology for use with COVID-19 lateral flow diagnostic tests.
The agreement with the Department of Health & Social Care follows an announcement that it had signed an exclusive licence and development agreement with Excalibur Healthcare Services Limited to apply MagnifEye for use with lateral flow rapid diagnostic tests.
Lord Paul Drayson PhD, CEO of Sensyne Health, said: “We are delighted to be working with the Department of Health & Social Care and Excalibur and are happy to be able to contribute to the UK’s COVID-19 testing programme by providing our MagnifEye technology for use with lateral flow diagnostic tests and look forward to the results of this pilot study.”
Want the latest science news straight to your inbox? Become a SelectScience member for free today>>